Hutchison China MediTech Limited (HCM) Sees Significant Increase in Short Interest

Hutchison China MediTech Limited (NASDAQ:HCM) saw a large increase in short interest during the month of April. As of April 28th, there was short interest totalling 29,758 shares, an increase of 9.9% from the April 13th total of 27,085 shares. Based on an average daily trading volume, of 17,592 shares, the days-to-cover ratio is currently 1.7 days.

Shares of Hutchison China MediTech Limited (NASDAQ HCM) traded down 1.70% during mid-day trading on Tuesday, hitting $23.19. 13,252 shares of the company were exchanged. The stock has a market cap of $2.81 billion, a PE ratio of 236.63 and a beta of -1.56. Hutchison China MediTech Limited has a 12-month low of $10.61 and a 12-month high of $23.80. The stock’s 50-day moving average price is $20.31 and its 200 day moving average price is $16.90.

A number of equities analysts have recently issued reports on HCM shares. Canaccord Genuity set a $20.00 price target on shares of Hutchison China MediTech Limited and gave the company a “buy” rating in a report on Saturday, March 11th. Zacks Investment Research downgraded shares of Hutchison China MediTech Limited from a “hold” rating to a “sell” rating in a report on Monday, May 15th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $22.00 target price (up from $20.00) on shares of Hutchison China MediTech Limited in a research report on Tuesday, March 14th.

A number of hedge funds and other institutional investors have recently bought and sold shares of HCM. Candriam Luxembourg S.C.A. bought a new position in Hutchison China MediTech Limited during the first quarter worth $2,035,000. Schroder Investment Management Group increased its position in shares of Hutchison China MediTech Limited by 6.8% in the first quarter. Schroder Investment Management Group now owns 976,364 shares of the company’s stock valued at $20,084,000 after buying an additional 62,045 shares in the last quarter. Prudential PLC increased its position in shares of Hutchison China MediTech Limited by 41.0% in the fourth quarter. Prudential PLC now owns 1,842,055 shares of the company’s stock valued at $24,997,000 after buying an additional 535,618 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Hutchison China MediTech Limited by 2.7% in the first quarter. Baillie Gifford & Co. now owns 157,892 shares of the company’s stock valued at $3,150,000 after buying an additional 4,189 shares in the last quarter. Finally, Waverton Investment Management Ltd increased its position in shares of Hutchison China MediTech Limited by 16.5% in the first quarter. Waverton Investment Management Ltd now owns 140,988 shares of the company’s stock valued at $2,813,000 after buying an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 4.83% of the company’s stock.

WARNING: “Hutchison China MediTech Limited (HCM) Sees Significant Increase in Short Interest” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thestockobserver.com/2017/06/20/short-interest-in-hutchison-china-meditech-ltd-hcm-rises-by-9-9-updated-updated-updated-updated.html.

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply